Our findings establish FABP4, CDR2L, and FSTL3 as pivotal regulators at the CRC-diabetes interface, with dual utility as prognostic indicators and predictors of immunotherapy efficacy. This evidence concerns the gene CDR2L and diabetes mellitus.